Head to Head Contrast: Establishment Labs (ESTA) vs. ConforMIS (CFMS)

Share on StockTwits

Establishment Labs (NASDAQ:ESTA) and ConforMIS (NASDAQ:CFMS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Establishment Labs and ConforMIS, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Establishment Labs 0 0 3 0 3.00
ConforMIS 1 0 5 0 2.67

Establishment Labs presently has a consensus target price of $35.00, suggesting a potential upside of 65.96%. ConforMIS has a consensus target price of $3.75, suggesting a potential upside of 321.35%. Given ConforMIS’s higher probable upside, analysts clearly believe ConforMIS is more favorable than Establishment Labs.

Institutional & Insider Ownership

40.2% of ConforMIS shares are owned by institutional investors. 7.6% of ConforMIS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


This table compares Establishment Labs and ConforMIS’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Establishment Labs N/A N/A N/A
ConforMIS -64.66% -94.69% -50.85%

Valuation and Earnings

This table compares Establishment Labs and ConforMIS’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Establishment Labs $34.68 million 12.45 -$34.90 million N/A N/A
ConforMIS $78.11 million 0.72 -$53.58 million ($1.24) -0.72

Establishment Labs has higher earnings, but lower revenue than ConforMIS.


Establishment Labs beats ConforMIS on 6 of the 11 factors compared between the two stocks.

Establishment Labs Company Profile

Establishment Labs Holdings Inc., a medical technology company, designs, develops, manufactures, and markets medical devices for aesthetic plastic surgery, reconstructive plastic surgery, and aesthetic dermatology. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue. The company sells its products through exclusive distributors and direct sales force in 60 countries worldwide. Establishment Labs Holdings Inc. was founded in 2004 and is headquartered in Alajuela, Costa Rica.

ConforMIS Company Profile

ConforMIS, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides ConforMIS Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, and Monaco. ConforMIS, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply